ARMI | BioFabUSA Roadmap Reports

ARMI, with its BioFabUSA and NextFab stakeholders, has renown insights and experiences that it leverages to identify and solve complex problems impacting the healthcare and associated industries. ARMI has worked with partners to maximize, collate and facilitate stakeholder engagement to develop priority reports and roadmaps.

BioFabUSA Core Roadmaps

Technical Roadmap

The ARMI | BioFabUSA 2020 Technical Roadmap report outlines and describes a consensus-based list of technology development tasks aimed at achieving the vision for scalable, consistent, and cost-effective manufacturing of cells, tissues and organs.

Roadmap for BioFabUSA Education and Workforce Development

The Education and Workforce Development roadmap identifies highly needed skills for the biofabrication field. The workforce needs skills that reflect the integrated nature of the industry, where technology bridges cell biology, engineering, automation, regulatory and data analytics.

Special Reports

Essential Medicines Supply Chain and Manufacturing Resilience Assessment

Led by the U.S. Department of Health and Human Services (HHS) Office of the Assistant Secretary for Preparedness and Response and ARMI’s Next Foundry for American Biotechnology (NextFAB), the Essential Medicines Supply Chain and Manufacturing Resilience Assessment report outlines the supply chain vulnerabilities – specifically those affecting critical medicines on the FDA’s Essential Medicines List.

National Technology Roadmap for Pandemic Response and Recovery

This roadmap, driven by the manufacturing sector, outlines a technology-based action plan for strengthening and accelerating U.S. pandemic response and preparedness.

BioFabUSA, a program of ARMI, is a public-private partnership with more than 170 members, including companies, academic institutions and not-for profit organizations.




Learn more about work underway to build the biofabrication ecosystem and accelerate the science of regenerative medicine.